UHN

Report to Our Community 2021–2022

UNIVERSITY HEALTH NETWORK

TABLE OF CONTENTS

UHN 2020-21
Report to Our Community

Opening Message

We want to begin this year's *Report to our Community* by expressing our sincere gratitude to all members of TeamUHN for another tremendous year. Despite facing very real pressures, each member of TeamUHN went over and above to build A Healthier World, in service of patients, their families, and our communities. We are proud and deeply inspired by your resilience and response.

As has been the case throughout the pandemic, UHN continued to be a trusted partner and leader supporting the provincial and federal response to COVID-19. This past year brought about new challenges through new waves of the pandemic, putting an enormous strain on our system and our team members. However, we continued to find ways to support response and recovery efforts, while maintaining our position as one of the top hospitals in the world. Together with our partners, we undertook many efforts to care for those in need and protect the most vulnerable and those at highest risk across our communities.

UHN's commitment to the health of the population and the social determinants of health were on full display during these challenging times. With our support for high-use clients in ERs, vaccine programs for equity-deserving, at-risk populations, a partnership with the City of Toronto and the United Way, as well as breaking ground for "prescribed housing," we are advancing the agenda for those most in need.

Over the last year, UHN accelerated a virtual care model, which saw virtual visits increase from 250 (pre-pandemic) to as much as 10,000 visits per week. We also found new and innovative ways of providing timely access to care for our patients through our partnership with Sunnybrook and Unity Health and the expansion of our virtual Emergency Department.

In addition to caring for the sickest COVID patients in the country, TeamUHN continued to provide exemplary care for patients with cancer, cardiac disease, neurosciences, mental health and addictions, organ transplantation, complex medical, surgical, and rehab needs, and more. We saw new models and approaches to care developed and implemented, as well as innovative ideas introduced to decrease the surgical backlog.

We pushed forward UHN's clinical transformation by preparing for a safe, effective transition to a new health information system powered by Epic – an achievement that came to fruition with go-live in June 2022. The project to build a modern digital infrastructure, code-named Synapse to symbolize the interconnections created by a single source of truth for each patient's medical journey, demanded a tremendous amount of work and commitment from TeamUHN.

We forged ahead with our strategic priority to empower and invest in a diverse TeamUHN, as well as our work of identifying and removing institutional racism in accordance with UHN's Anti-Racism and Anti-Black Racism policy. We called on all TeamUHN members to create a safe, inclusive culture, and to stand in solidarity with Black, Indigenous, and People of Colour, while clearly condemning hate and bigotry in all its vile forms.

UHN Research was again at the forefront of cutting-edge and innovative discoveries, from uncovering a way to make universal organs that can be transplanted regardless of blood type to a new way to classify brain tumours that may outperform the current approach and the mapping out of the cellular origins and genetic events that lead to an aggressive form of leukemia in children with Down syndrome.

The Michener Institute of Education at UHN continued to both educate and inspire future healthcare professionals and think differently about how to solve Canada's health human resources challenges. The institute moved to fill system gaps with new and revised programs, including digital health and data analytics, and became the first Canadian school to offer a Master's degree in cardiovascular perfusion. Michener's partnerships with Nova Scotia and Saskatchewan set Michener up to pursue its goal of ensuring Canada has the health professionals it needs in growing, in-demand fields.

We continued to make investments in TeamUHN, with People and Culture showing proactive leadership to address staffing challenges through recruitment and retention measures, including an employee referral program to reward TeamUHN members for bringing new candidates to UHN and a comprehensive nursing retention strategy. We also enhanced the mental health benefit to ensure all staff enrolled in our group benefits plan could access expanded mental health coverage as a consequence of COVID.

The amazing generosity from our Foundations this year reminded TeamUHN members that the work they do is so valued. From meal vouchers and snacks provided to frontline staff to the Rest Safe program that provided accommodations for staff in between shifts at downtown Toronto hotels, limiting the risks that they would bring COVID-19 home to their families, the support was so appreciated. The generosity of donors and our Foundations also let us continue our top-calibre and world-renowned research and education.

Some accomplishments from last year that are worth noting include:

UHN (Toronto General Hospital) named the No. 4 hospital in the world by U.S Newsweek

- Recognized as one of the top five hospitals for the third consecutive year.
- Named Canada's top research hospital for the 10th consecutive year.
- Gold Winner of the Ashikaga-Nikken Excellence Award for Green Hospitals at the International Hospital Federation Awards in Spain, for demonstrating excellence in promoting environmental sustainability.
- Dr. John Dick, Senior Scientist at Princess Margaret Cancer Centre, received the 2022 Canada Gairdner International Award "for the discovery and characterization of leukemic stem cells, providing insights into the understanding, diagnosis, and treatment of acute myeloid leukemia."
- The team from The Michener Institute of Education at UHN and University Health Network won the 2021 Ted Freedman Award for Innovation in Education in recognition of the COVID Care Learning platform.

UHN continued to make advancements and commitments to provide high-quality patient care

- Adela, a start-up launched based on epigenetic research that seeks to identify cancer and other diseases with a simple blood test, secured $US60 million in financing.
- Opened three state-of-the-art organ repair labs at the Sprott Department of Surgery operating rooms at Toronto General Hospital after more than a year of construction.
- Launched UHN's first Indigenous healing garden at The Michener Institute of Education.
- Started construction of the first-of-its-kind-in Canada Social Medicine Supportive Housing project in the Parkdale neighbourhood, a collaborative initiative between UHN's Gattuso Centre for Social Medicine, United Way Greater Toronto, the City of Toronto, and the community to provide safe, affordable housing for 51 people with complex health needs.
- Achieved many world firsts, including the first transport of lungs intended for transplant by an unmanned aerial drone, the first randomized placebo-controlled trial of third dose booster vaccine for transplant patients, and the first use of PET/MRI scans to measure heart injury in recovered COVID-19 patients.

Significant investments were made to enhance UHN's footprint and expand care delivery

- Secured significant government support, including: a $24 million New Frontiers grant from the Government of Canada to advance ex vivo technology.
- A $34 million planning grant from the Province of Ontario for an 11-story New Patient Tower at Toronto Western Hospital
- A $4.8 million investment from the provincial government to expand Princess Margaret Cancer Centre, including a new unit for the Stem Cell Transplant Program
- A $5 million planning grant from the Province of Ontario to help establish Canada's first hospital-based proton radiation therapy centre
- A $12.1 million investment from Ontario to support UHN's Hillcrest Reactivation Centre.

UHN is grateful for the generous donors for continuing to support our organizations purpose, mission and values

- Generated $16 million in licensing revenue during the fiscal year, part of $81 million raised over the last four years.
- Received historic philanthropic donations, including a $50-million gift from Donald K. Johnson to the Donald K. Johnson Eye Institute at UHN and a $50-million gift to the Princess Margaret Cancer Foundation from *La Fondation Emmanuelle Gattuso* and The Slaight Family Foundation.

We remain firmly confident that TeamUHN will continue to advance world-class care, research, and education, and continue to inspire and amaze. We hope that you share our pride in UHN for all that has been accomplished and excitement for the new heights we will reach together.

We thank you all for your unrelenting commitment to TeamUHN, the patients we are so privileged to serve, and *A Healthier World*.

Dr. Kevin Smith
President & CEO, UHN

Mr. Brian J. Porter
Chair, UHN Board of Trustees

UHN
Toronto General
Toronto Western
Princess Margaret
Toronto Rehab
Michener Institute

UNIVERSITY OF TORONTO

University Health Network is a teaching hospital affiliated with the University of Toronto

Overview

UHN is Ontario and Canada's premier academic health sciences centre serving the most acute patients and our local community. The world-class care, research, and education at UHN encompass everything from basic discovery to clinical and policy research in many areas, including cardiac, cancer, neurological diseases, rehab, transplant, arthritis and more.

The great contributions in health research made at UHN to improve the province's healthcare system not only support innovation but are also integral to the economic development and growth of Ontario and Canada, which is needed now more than ever as we embark on the road to recovery from COVID-19.

From a care delivery perspective, UHN continues to be a leader in our healthcare system. Working with our partner hospitals when they are no longer able to treat Ontario's sickest patients, they rely on TeamUHN to address patient needs from assessment and treatment through to recovery.

In this sense, UHN fulfills two very important roles – as a community hospital and care provider for the growing population in Toronto's downtown core, as well as a leading academic teaching and learning centre with specialty programs driving local, national, and international impact.

UHN's 12 programs provide a comprehensive range of locally accessible services alongside a number of specialized provincial programs including:

- **Cancer:** World-renowned clinical trials program at **Princess Margaret Cancer Centre**. We perform 1 in 2 of all allogeneic stem cell transplants in the province.
- **Transplant: UHN's Ajmera Transplant Centre** is the only centre in Ontario with the expertise to transplant all organ types.
- **Cardiac: The Peter Munk Cardiac Centre** is Ontario's only centre providing care for complex adult congenital patients – we receive all children treated for congenital heart surgery at SickKids.
- **Neuro: The Krembil Brain Institute** provides 85% of Ontario's adult deep brain stimulation volumes – and is one of the only provincial providers of neuromodulation services.
- **Arthritis: The Schroeder Arthritis Institute** provides Canada's largest multi-disciplinary arthritis program with more than 80,000 outpatients each year and an international reputation for innovative research and exceptional patient care.

UHN is a leader in improving access and integration of care for equity-deserving populations through our **Population Health & Social Medicine** program. A number of new partnerships for UHN have been forged through this work (which have been expedited through our COVID-19 response efforts), and will be critical to addressing driving factors behind high health care utilization while improving overall health outcomes in our local community.

Instrumental to the reach and impact of our clinical programs are UHN's **Research & Education Programs**, including the only health-focused educational entity tied to an academic hospital in Canada - The Michener Institute of Education. These programs enable and uniquely position UHN to undertake major projects across the continuum of research and education, and focus on areas where we can be a leader to address society's most important challenges.

UHN is active in numerous provincial initiatives and specialty committees at the request of the ministry, Ontario Health, and other key stakeholders, as well as part of the Toronto Academic Health Science Network. We are pleased to be assuming an additional leadership role in a ministry-funded Cybersecurity initiative in the fiscal year 2022/23.

Strategic plan

UHN's 2019-2023 Strategic Plan – *A Healthier World* – outlines our core priorities for excellence in care, discovery, and learning. It calls on us to:

- Inspire, invent and deliver tomorrow's care
- Empower and invest in a diverse TeamUHN
- Drive the convergence of care, research, and education
- Unleash the power of technology and innovation
- Elevate Canada as a world destination for commercialization and discovery

Despite the challenges of the pandemic, UHN has made significant progress this fiscal year on many of these established strategic and operational priorities. These include:

- Significant work across UHN to ensure that a new modern **Health Information System (Epic)**, set to supercharge UHN's path to clinical transformation, was implemented in June 2022.
- Targeted organizational resources, strategies, and new programs to advance UHN's efforts to deliver the **future of integrated care**, including via implementation of a new Outpatient & Virtual Care Strategy.
- Development of **educational program enhancements and new curricula** through The Michener Institute of Education to enable current and future healthcare professionals to address the system's most pressing resourcing needs.
- Development of our new **Integrated Master Facility Plan 2021-2026** that outlines important capital investments that will support critical clinical services and drive near-term innovation capacity across care, research and learning.
- Release of our new **Commercialization Strategy 2021-2026** to build a clear roadmap for inspiring, inventing, and delivering tomorrow's care.

Dr. Gonzalo Sapisochin, a transplant surgeon at UHN's Ajmera Transplant Centre and the Sprott Department of Surgery at UHN, is seen here in the operating room, performing liver surgery. (Photo: UHN)

Some highlights of the year from UHN News

Living donation opens doors for colorectal cancer patients in need of liver transplant

A study published in the Journal of the American Medical Association Surgery is the first in North America to demonstrate that living-donor liver transplant is a viable option for patients who have systemically controlled colorectal cancer and liver tumours that cannot be surgically removed.

"This study proves that transplant is an effective treatment to improve quality of life and survival for patients with colorectal cancer that metastasized to the liver," said study senior author Dr. Gonzalo Sapisochin, a transplant surgeon at UHN's Ajmera Transplant Centre and the Sprott Department of Surgery at UHN.

"As the first successful North American experience, it represents an important step towards moving this protocol from the research arena to standard of care," adds Dr. Sapisochin, who is also a clinician-investigator at the Toronto General Hospital Research Institute and an Associate Professor in the Department of Surgery at University of Toronto.

Read more at UHN News

Ken and Joan Taylor have gifted nearly $3 million to The Princess Margaret Cancer Foundation to further research into multiple myeloma. Ken was diagnosed with the blood cancer in 2009. (Photo: The PMCF)

Taylor family's philanthropy drives big and bold ideas in multiple myeloma research

In January 2009, Ken and Joan Taylor were on one of their regular work trips to beautiful Hilton Head, S.C. where they founded Spinnaker Resorts in the early 1980s. Unfortunately, their trip took a turn for the worse. Ken was admitted to the hospital with a serious case of pneumonia.

To their surprise, Ken received an unexpected and startling diagnosis during his hospital stay: multiple myeloma.

With no known cure, multiple myeloma, also known as myeloma, is a blood cancer associated with the uncontrolled growth and abnormal behaviour of plasma cells – the white blood cells made in the bone marrow that help the body fight infection. Myeloma develops when abnormal plasma cells – cancerous cells known as myeloma cells – accumulate, making it difficult for healthy blood cells to properly develop and function.

Read more at UHN News

For more than 60 years, The Michener Institute of Education at UHN has educated generations of healthcare professionals, providing a broad range of full-time, part-time and continuing education programs designed to meet emerging and evolving applied health sciences needs within Ontario's healthcare system. (Photo: UHN)

Michener model expanding to build capacity across Canada

With new agreements in two provinces over the past two months, The Michener Institute of Education at UHN is accelerating its long-term goal of ensuring Canada has an adequate supply of critically-needed health professionals.

"Since it was created in 1958, Michener has been a jewel in Ontario's higher education and healthcare crown," says Michener Principal Dr. Harvey Weingarten. "It is unlike any other institution in Canada in how it is designed to solve some of Canada's most challenging health human resource needs."

In early March, Michener entered into a partnership in Saskatchewan that will increase training capacity and open doors for those seeking careers in the growing field of medical imaging. This Memorandum of Understanding (MOU), with the National Medical Imaging Clinic, Education & Research Centre and the James Smith Cree Nation, will create Saskatchewan's first MRI technologist training program.

Read more at UHN News

Helping kick off the construction of the Social Medicine Supportive Housing project in Parkdale were: (L to R) Arif Virani, MP for Parkdale-High Park, the Honourable Ahmed Hussen, Minister of Housing and Diversity and Inclusion, Daniele Zanoti, President and CEO, United Way Greater Toronto, Dr. Kevin Smith, President & CEO of UHN, Toronto Deputy Mayor Ana Bailao, Toronto Mayor John Tory and Gord Perks, City Councillor, Ward 4, Parkdale-High Park. (Photo: UHN)

UHN and partners kick off construction of Social Medicine Supportive Housing in Parkdale

UHN and partners announced Friday the start of construction on the first-of-its-kind-in-Canada Social Medicine Supportive Housing in the Parkdale neighbourhood.

The project, delivered in partnership between UHN's Gattuso Centre for Social Medicine, United Way Greater Toronto (UWGT), the City of Toronto and community, has support from all levels of government.

The four-storey modular building at 150 Dunn Avenue – currently a parking lot of UHN's EW Bickle Centre for Complex Continuing Care – will provide 51 people from historically marginalized groups who are frequent users of hospital services with accessible, safe, secure and affordable housing.

"We have seen people who are surviving homelessness suffer some of the worst health outcomes, both before and during the pandemic," said Dr. Andrew Boozary, Executive Director of the Gattuso Centre.

Read more at UHN News

The groundbreaking research of (L to R) Drs. John Dick, Jayne Danska and Jean Wang ultimately led to pharmaceutical giant Pfizer Inc. acquiring Trillium Therapeutics for US$2.22 billion. (Photo: UHN)

Discovery behind blockbuster Pfizer-Trillium deal started at UHN and SickKids

"Don't Eat Me"

It's a simple biological message whispered by crafty cancer cells to the immune system as they attempt to spread, grow and avoid destruction.

But the complex work to understand and control that signal, which gives those dangerous cells the power to hide, has taken decades of research to understand. Last year, the story took a new twist when it spurred pharmaceutical giant Pfizer Inc.'s acquisition of Trillium Therapeutics in a US$2.22 billion deal.

The groundbreaking research that led to the deal started at UHN's Princess Margaret Cancer Centre and The Hospital for Sick Children (SickKids).

Read more at UHN News

Dr. Aizhou Wang, first author of the study, demonstrates in the lab how the enzymes enter the Ex Vivo Lung Perfusion (EVLP) system, treating organs so they become 'universal.' (Photo: UHN)

Creating universal blood-type organs for transplant

A study published in Science Translational Medicine performed at the Latner Thoracic Surgery Research Laboratories and UHN's Ajmera Transplant Centre has proved that it is possible to convert blood type safely in donor organs intended for transplantation.

This finding is an important step towards creating universal type O organs, which would significantly improve fairness in organ allocation and decrease mortality for patients in the waitlist.

"With the current matching system, wait times can be considerably longer for patients who need a transplant depending on their blood type," explains Dr. Marcelo Cypel, Surgical Director of the Ajmera Transplant Centre and the senior author of the study.

Read more at UHN News



Astrocytes (purple) are a type of brain cell that support neurons (light blue). One of their many functions is to help regulate signal transmission. (Photo: Getty Images)

Cleaning up after neurons

Researchers at UHN's Krembil Brain Institute have shown that stimulating a specialized type of brain cell – known as astrocytes – can correct chemical imbalances associated with disorders such as migraine and epilepsy.

When the brain is active, concentrations of charged molecules called ions change, allowing for messages to be transmitted. A particular ion – potassium – accumulates outside these cells in high concentrations after brain activity. Astrocytes, a type of support cell that helps to regulate signal transmission, normally help to take up excess potassium.

Read more at UHN News

The study was led by Drs. Suneil Kalia, (L), and Lorraine Kalia, both Senior Scientists at UHN's Krembil Brain Institute. (Photo: Brian Simon)

A worm's eye view for drug discovery

Researchers at UHN's Krembil Brain Institute have developed an experimental model for early-stage Parkinson's disease using Caenorhabditis elegans, a small transparent worm.

They also incorporated the model into a drug-screening pipeline to rapidly identify potential therapies for Parkinson's disease.

Currently, experimental models of early-stage Parkinson's disease are limited. Such models are needed for the discovery of new therapies.

Read more at UHN News



Dr. Housheng (Hansen) He, Senior Scientist, Princess Margaret Cancer Centre, is a co-senior author of the study. (Photo: UHN)

Researchers at the Princess Margaret provide new insights into possible therapeutic pathway for colorectal cancer

Princess Margaret Cancer Centre researchers have discovered the potential for a new therapeutic pathway to treat metastatic colorectal cancer using the technology behind some of the most successful COVID-19 vaccines.

The PM team have discovered the possible therapeutic target for the deadly disease by delving into the function of a gene which appears to hold the key to slowing or limiting spread of the illness. The study found that the YTHDF1 gene increases the protein production of ARHGEF2 through a mechanism called RNA-epigenetics, which leads to growth of the disease, and in particular, the metastasis of colorectal cancer.

The results of the research were published recently in the journal Gastroenterology. Dr. Housheng (Hansen) He, Senior Scientist at the Princess Margaret Cancer Centre, and Dr. Jun Yu, Professor at the Chinese University of Hong Kong, are co-senior authors of the study.

Read more at UHN News

Dr. Rajat Kumar, Head of Malignant Hematology at Princess Margaret Cancer Centre, and the stem cell transplant team supervised the first stem cell transplant of an adult with sickle cell illness to achieve a cure. (Photo: Visual Services, UHN)

UHN offers cure for adults with sickle cell disease

UHN has cured an adult of sickle cell disease with a stem cell transplant from a sibling donor, freeing the patient forever from constant blood transfusions and medical complications related to the illness.

“The main therapies for adult sickle cell patients are those that treat symptoms and attempt to control disease, such as transfusions, pain medication or even hospital admissions for extreme pain,” says Dr. Richard Ward, Medical Director of the Red Blood Cell Disorders Clinic at Toronto General Hospital (TGH), adding that a transplant represents a cure for a life-long, debilitating disease.

Read more at UHN News

(L to R) Martine Rothblatt, Shaf Keshavjee, Mikael Cardinal, Andrew Sage and Kevin Smith were on Toronto General's rooftop for this historic flight. (Photo: Unither Bioélectronique/Jason van Bruggen)

Toronto Lung Transplant Program and Quebec company transport lungs by drone

In an exciting world-first, lungs intended for transplant were transported by an unmanned aerial drone from UHN's Toronto Western Hospital to Toronto General Hospital.

The few-minutes flight happened in late September and was led by the Toronto Lung Transplant Program in partnership with Quebec-based biotechnology aviation company Unither Bioélectronique, with support from Trillium Gift of Life Network (TGLN) – the organization in charge of organ and tissue donation in Ontario.

"This is an incredibly important milestone for our program, and for the medical field of transplantation," says Dr. Shaf Keshavjee, Director of the Toronto Lung Transplant Program at UHN's Ajmera Transplant Centre.

Read more at UHN News

Drs. Akihiro Nakamura and Nigil Haroon study axial spondyloarthritis (SpA), a painful and debilitating form of arthritis that causes inflammation in the spine, joints, eyes, gut and skin. (Photos: UHN)

Discovery of a potential new therapy for inflammatory arthritis

Susan Rivers was only 10 years old when she began experiencing pain in the joints in her legs.

After many years of suffering and few answers, Susan was diagnosed with ankylosing spondylitis, a painful and inflammatory form of axial spondyloarthritis (SpA), which affects one per cent to two per cent of Canadians and causes inflammation in the spine, joints, eyes, gut and skin.

In a new paper recently published in the journal Science Translational Medicine, researchers at the Schroeder Arthritis Institute at UHN have made a discovery that could lead to new treatments for SpA.

"We currently have very few therapeutic options for the majority of patients living with SpA and this is a debilitating disease that directly impacts quality of life," says Dr. Nigil Haroon, a rheumatologist, co-Director of the Spondylitis Program and senior author on the paper.

Read more at UHN News

Financial Highlights

For the year ended March 31, 2022
(in thousands of dollars)

Full audited statements are available at: www.uhn.ca

REVENUE	$
Ontario Ministry of Health and Ontario Health	1,729,680
Other patient services	225,349
Grants and donations for research and other purposes	342,698
Ancillary services and other	454,389
Amortization of deferred capital contributions	66,336
	2,818,452

EXPENSES	$
Compensation	1,640,611
Medical, surgical supplies and drugs	465,969
Other supplies and expenses	405,185
Plant operations and equipment maintenance	154,918
Amortization	119,584
Interest on long-term liabilities	23,407
	2,809,674
Excess of revenue over expenses for the year	**8,778**

ASSETS	$
CURRENT	
Cash and cash equivalents	556,835
Accounts receivable	353,037
Inventory	24,583
Prepaid expenses	33,515
LONG TERM	
Loans receivable	1,250
Capital assets, net	1,474,057
Long-term investments	628,459
	3,071,736

LIABILITIES AND NET ASSETS	$
CURRENT	
Accounts payable and accrued liabilities	1,113,354
Current portion of long-term liabilities	28,643
LONG TERM	
Due to MaRS Development Trust	61,443
Deferred research contributions	419,564
Long-term debt	108,447
Employee future benefit liabilities	53,069
Deferred capital contributions	691,367
	2,475,887
NET ASSETS	
Internally restricted	156,284
Unrestricted	438,114
	594,398
Accumulated remeasurement gains	1,451
	595,849
	3,071,736

Statistical Report

Program Grouping Activity
2021/22

UHN	Inpatient Separations*	Inpatient Weighted Cases+	CCC RUG Weighted Patient Days**	Day Surgery Cases ~	Day Surgery Weighted Cases^	Ambulatory Visits *~
Acute	34,784	91,837		27,914	8,113	1,189,784
Rehab	2,413	3,853				
Complex Continuing Care (CCC)	799		75,912			
Rehab & CCC Combined						66,579
Total	**37,996**	**95,690**	**75,912**	**27,914**	**8,113**	**1,256,363**

* Data is based on General Ledger for Acute, Rehab, and CCC, PHS for Rehab & CCC Ambulatory Visits; + 2021 HIG Weights for Acute, 2021 RPG Weights for Rehab; ** 2021 RUG III Grouper, ~ Coding (NACRS); ^ 2021 CACS ON Weights; *excludes radiation fractions and Emergency visits

Site Activity
2021/22

Site	Beds	Inpatient Days	Clinic & Day/Night Care Visits	Emergency Visits
TGH	463	153,438	427,874	51,848
TWH	280	97,817	437,107	60,432
Princess Margaret	162	48,822	324,803	
TRI - Bickle Centre	228	70,340	2,253	
TRI - University Centre	133	53,250	32,478	
TRI - Lyndhurst Centre	54	19,795	8,057	
TRI - Rumsey Centre			23,791	
UHN Total	**1,320**	**443,462**	**1,256,363**	**112,280**

Research Activity by Institute 2021/22
(in thousands of dollars)

Princess Margaret Cancer Centre *Cancer Research*	240,950
Toronto General Hospital Research Institute *Cardiac, Communities of Health, Critical Care, Diabetes & Metabolism, Infectious Diseases, Liver, Nephrology, Respiratory, Transplant*	113,611
Krembil Research Institute *Brain, Vision, Arthritis*	67,706
KITE (Knowledge. Innovation. Talent. Everywhere) *Rehabilitation*	26,841
TECHNA *Technology for Improved Health*	13,548
McEwen Stem Cell Institute *Stem Cell Research*	9,167
The Institute for Education Research (TIER) *Research Education*	2,751
Total	**474,574**

Trends Report

Inpatient and Outpatient Activity
(in thousands)

Revenue
(in millions of dollars)

External Research Funding
(in millions of dollars)



UHN
Toronto General
Toronto Western
Princess Margaret
Toronto Rehab
Michener Institute

UNIVERSITY OF TORONTO